Skip to main content

Table 2 Differences in the complete response of CINV symptoms among the study groups

From: Effects of auricular acupressure on chemotherapy-induced nausea and vomiting in breast cancer patients: a preliminary randomized controlled trial

MAT Outcomes a

True AA

Sham AA

Standard Care

Chi-square Test

Effect Size

Post-hoc Analysis c

True vs. Sham

True vs. SC

Sham vs. SC

n b

No. of CR (%)

n

No. of CR (%)

n

No. of CR (%)

Value

p

Cramer’s V

Value

p

Value

p

Value

p

CR of overall CINV

37

11 (29.7%)

38

11 (28.9%)

38

5 (13.2%)

3.64

0.16

0.18

NA

NA

NA

NA

NA

NA

CR of acute CINV

38

20 (52.6%)

38

17 (44.7%)

38

9 (23.7%)

7.07

0.03

0.25

0.47

0.49

6.75

0.01

3.74

0.05

CR of delayed CINV

37

16 (43.2%)

38

16 (42.1%)

38

13 (34.2%)

0.76

0.68

0.08

NA

NA

NA

NA

NA

NA

CR of overall nausea

37

11 (29.7%)

38

11 (28.9%)

38

5 (13.2%)

3.64

0.16

0.18

NA

NA

NA

NA

NA

NA

CR of overall vomiting

37

24 (64.9%)

38

24 (63.2%)

38

17 (44.7%)

3.85

0.15

0.19

NA

NA

NA

NA

NA

NA

  1. This table is derived and modified from the original PhD thesis of Professor Jing-Yu (Benjamin) Tan [Tan, J. (2017). Effects of auricular acupressure on chemotherapy-induced nausea and vomiting in breast cancer patients: a preliminary randomized controlled trial. Doctoral dissertation, The Hong Kong Polytechnic University, Hong Kong.] [28]
  2. CINV chemotherapy-induced nausea and vomiting, MAT MASCC Antiemesis Tool, AA auricular acupressure, SC standard care, CR complete response, NA not applicable
  3. aCR of overall CINV: no nausea and vomiting from day 1 to day 5 of the first chemotherapy cycle; CR of acute CINV: no nausea and vomiting during day 1 of the first chemotherapy cycle; CR of delayed CINV: no nausea and vomiting from day 2 to day 5 of the first chemotherapy cycle; CR of overall nausea: no nausea from day 1 to day 5 of the chemotherapy cycle; CR of overall vomiting: no vomiting from day 1 to day 5 of the chemotherapy cycle
  4. bone participant from the true AT group dropped out during the delayed CINV assessment. ITT analysis using the acute phase data as the delayed outcomes is not appropriate here because the delayed CINV symptom is different from the acute CINV symptom in nature. No ITT approach was utilized in this analysis; therefore, the available sample size for calculating the CR of the overall CINV, delayed CINV, overall nausea, and overall vomiting in the true AT group was 37
  5. cpartitioning Chi-square statistics were applied for the post-hoc analysis